Donovan Quill, President and CEO, Optime Care, article featured in Healthcare Business Today on August 16, 2021.
Clinical research professionals wanting to build a go-to market strategy often feel overwhelmed and may seek advice from a so-called “pharma strategy expert.” Unfortunately, this term is confusing, given that it’s impossible to provide expertise across the wide range of therapies for rare and orphan conditions. Each patient is unique in terms of treatment, points of care, physicians and level of caregiving they require.
Most rare disease “experts” understand big pharma or are skilled at strategizing commercialization, but too often they offer an ever-increasingly complicated process that fails to be cost-effective.
This article emphasizes the importance of putting the patient first to allow dedicated clinical teams to seamlessly eliminate treatment gaps for the patient. This strategy also addresses all variables around collecting data, while maintaining frequent communication with patients and their families to ensure compliance and positive outcomes.
The ideal specialty pharmacy and patient management partner should offer a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of rare and orphan disorders.
